Review: Peptidases and peptidase inhibitors in the pathogenesis of diseases: Disturbances in the ubiquitin-mediated proteolytic system. Protease-antiprotease imbalance in inflammatory reactions. Role of cathepsins in tumour progression

Advances in Experimental Medicine and Biology

Volumn 477, Issue , 2000, Pages 349-378

  Bank, Ute ^a   Krüger, Sabine ^a   Langner, Jürgen ^b   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN L; PEPTIDASE; PEPTIDASE INHIBITOR; PROTEINASE INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; CONFERENCE PAPER; DISEASE COURSE; ENZYME INHIBITOR INTERACTION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION;

ALPHA 1-ANTITRYPSIN DEFICIENCY; ANGELMAN SYNDROME; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INFLAMMATION; LIGASES; LYSOSOMES; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MULTIENZYME COMPLEXES; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SERPINS; TISSUE INHIBITOR OF METALLOPROTEINASES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 0034471552     PISSN: 00652598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Predominant role of neutrophils in the inactivation of alpha 2-macroglobulin in arthritic joints
2. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model
3. Ubiquitin, cellular inclusions and their role in neurodegeneration
4. Human ageing impairs injury-induced in vivo expression of tissue inhibitor of matrix metalloproteinases (TIMP)-1 and -2 proteins and mRNA
5. The effect of the secretory leukocyte protease inhibitor on leukocyte proteases released during phagocytosis
6. Detachment and cytolysis of human endothelial cells by proteinase 3
7. Comparison of properties of membrane bound versus soluble forms of human leukocytic elastase and cathepsin G
8. Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation
9. The proteasome: A macromolecular assembly designed to confine proteolysis to a nanocompartment
10. Studies on the elastase-serum protein interaction. II. On the digestion of human a2-macroglobulin, an elastase inhibitor, by elastase
11. Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors
12. Cysteineprotease and tumor progression
13. Leukocyte elastase
14. Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins
15. Consequences of unbalanced protease in the lung: Protease involvement in destruction and local defense mechanisms of the lung
16. Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency
17. Tissue inhibitors of matrix metalloproteinases in cancer
18. The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin
19. Oncostatin M is a potent stimulator of alpha1-antitrypsin secretion in lung epithelial cells: Modulation by transforming growth factor-beta and interferon-gamma
20. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III
21. ER-associated and proteasome-mediated protein degradation: How two topologically restricted events came together
22. Activation of neutrophil collagenase by cathepsin G
23. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases
24. Multiple tissues express alpha 1-antitrypsin in transgenic mice and man
25. Enzymatic inactivation of human plasma C1-inhibitor and alpha 1- antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase
26. PAF-induced elastase-dependent neutrophil transendothelial migration is associated with the mobilization of elastase to the neutrophil surface and localization to the migrating front
27. Proteolytic cleavage of ICAM-1 by human neutrophil elastase
28. Role of the ubiquitin-proteasome pathway in NFkB activation
29. Stimulatory effect of inflammatory cytokines on alpha 1-antichymotrypsin expression in human lung-derived epithelial cells
30. The ubiquitin-mediated proteolytic pathway: Mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins
31. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3
32. Synthesis in E. coli of alpha 1-antitrypsin variants of therapeutic potential for emphysema and thrombosis
33. Structure and functions of the 20S and 26S proteasomes
34. Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
35. Effect of an inhibitor of matrix metalloproteinases on spontaneous osteoarthritis in guinea pigs
36. Secretory leukocyte protease inhibitor concentration increases in amniotic fluid with the onset of labour in women: Characterization of sites of release within the uterus
37. Proteolytic inactivation of alpha 1-proteinase inhibitor and alpha 1- antichymotrypsin by oxidatively activated human neutrophil metalloproteinases
38. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy
39. The role of neutrophil elastase in chronic inflammation
40. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis
41. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor
42. Preclinical and clinical studies of MMP inhibitors in cancer
43. In vitro transport of active alpha(1)-antitrypsin to the apical surface of epithelia by targeting the polymeric immunoglobulin receptor
44. Inhibition of elastase by a synthetic cotton-bound serine protease inhibitor: In vitro kinetics and inhibitor release
45. Seeing the wood for the trees: The forgotten role of neutrophils in rheumatoid arthritis
46. Effects of major-histocompatibility-complex-encoded subunits on the peptidase and proteolytic activities of human 20S proteasomes. Cleavage of proteins and antigenic peptides
47. The cysteine protease cathepsin B in cancer
48. Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: One of several arguments for protease/antiprotease imbalance in systemic vasculitis
49. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury
50. Prognostic significance of cathepsins B and L in primary human breast cancer
51. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite
52. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue
53. Molecular regulation, membrane association and secretion of tumor cathepsin B
54. Interactions of neutrophils and coagulation proteins
55. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid
56. Proteolysis, proteasomes and antigen presentation
57. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
58. Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought?
59. The ubiquitin-proteasome pathway: Review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions
60. Glomerular basement membrane damage in immunological glomerulonephritis
61. Neutrophils and renal failure
62. Degranulation and secretion by phagocytic cells
63. Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins
64. Ubiquitin degradation of transcription regulators
65. Myeloblastin
66. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis
67. Ubiquitination of the p53 tumor suppressor
68. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase
69. Degradation of cartilage proteoglycan by human leukocyte granule neutral proteases - A model of joint injury. I. Penetration of enzyme into rabbit articular cartilage and release of 35SO4-labeled material from the tissue
70. Ubiquitin-dependent protein degradation: A cellular perspective
71. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide
72. Proteolytic destruction of functional proteins by phagocytes in human peritonitis
73. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center
74. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
75. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
76. Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage
77. Latency of cathepsin B secreted by human colon carcinoma cells is not linked to secretion of cystatin C and is relieved by neutrophil elastase
78. How proteolysis drives the cell cycle
79. UBE3A/E6-AP mutations cause Angelman syndrome
80. Matrix metalloproteinases and metastasis
81. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)
82. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B
83. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes
84. Inhibition of tumour cell invasion by protease inhibitors: Correlation with the protease profile
85. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients
86. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
87. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer
88. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line
89. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma
90. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation
91. Human neutrophil elastase abolishes interleukin-8 chemotactic activity
92. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
93. A protein structural approach to the solution of biological problems: Alpha 1-antitrypsin as a recent example
94. The elastase-mediated pathway of fibrinolysis
95. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome
96. Inhibition of human immunodeficiency virus type I infectivity by secretory, leukocyte protease inhibitor occurs prior to viral reverse transcription
97. Biology and biochemistry of proteinases in tumor invasion
98. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway
99. Potency of truncated secretory leukoprotease inhibitor assessed in acute lung injury models in hamsters
100. Ligand-dependent polyubiquitination of c-kit gene product: A possible mechanism of receptor down modulation in M07e cells
101. Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI
102. Destruction of articular cartilage by alpha 2 macroglobulin elastase complexes: Role in rheumatoid arthritis
103. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: Relevance to stability of atherosclerotic plaque
104. Ligand-induced polyubiquitination of receptor tyrosine kinases
105. Transforming growth factor alpha in arterioles: Cell surface processing of its precursor by elastases
106. Stage-specific increases in cathepsin B messenger RNA content in human colorectal carcinoma
107. Purification and characterization of a novel cysteine proteinase (periodontain) from Porphyromonas gingivalis. Evidence for a role in the inactivation of human alpha1-proteinase inhibitor
108. Molecular basis, clinical consequences and diagnosis of alpha-1 antitrypsin deficiency
109. Enzymatic degradation of tumor necrosis factor by activated human neutrophils: Role of elastase
110. Bendless, a Drosophila gene affecting neuronal connectivity, encodes a ubiquitin-conjugating enzyme homolog
111. Distribution of the secretory leucocyte proteinase inhibitor in human articular cartilage
112. Cell surface-bound elastase and cathepsin G on human neutrophils: A novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases
113. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3
114. Matrix metalloproteinases
115. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice
116. The neutrophil in rheumatoid arthritis
117. Membrane-type metalloproteinases in tumor invasion
118. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNT receptors from stimulated neutrophils
119. Modulation of the transport of a lysosomal enzyme by PDGF
120. Interaction of secretory leukocyte protease inhibitor with proteinase-3
121. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
122. Specific sensitivity of CD43 to neutrophil elastase
123. Proteolytic control of growth factor availability
124. In vitro processing of human tumor necrosis factor-alpha
125. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
126. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells
127. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils
128. Cathepsin G
129. Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function
130. The ubiquitin-conjugatin system
131. The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G
132. Cathepsin-G and leukocyte elastase inactivate human tumor necrosis factor and lymphotoxin
133. Inhibition of motility and invasion of B16 melanoma by the overexpression of cystatin C
134. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by antirheumatic drugs
135. End of the line: Proteolytic degradation of cyclin-dependent kinase inhibitors
136. Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor
137. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens
138. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha l-antitrypsin
139. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene
140. Endoplasmic reticulum degradation: Reverse protein flow of no return
141. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis
142. Human neutrophils do not degrade major basement membrane components during chemotactic migration
143. Reducing neutrophil elastase-induced lung injury
144. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor
145. Molecular mechanisms of tumor cell metastasis
146. Oxidant-mediated inactivation of TIMP
147. Effect of anti-neutrophil cytoplasmic antibodies on proteinase 3- induced apoptosis of human endothelial cells
148. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L
149. Secretory leukoprotease inhibitor: A native antimicrobial protein presenting a new therapeutic option?
150. Human plasma proteinase inhibitors
151. Potential problems in designing elastase inhibitors for therapy
152. Synthesis and structure-activity relationships of elafin, an elastase- specific inhibitor
153. Effect of electrogingivectomy and elastase inhibitor on the enzymatic activity of the gingiva during the treatment of parodontosis
154. Epithelial cell damage is induced by neutrophil-derived, not pseudomonas-derived, proteases in cystic fibrosis sputum
155. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity
156. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative stress
157. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers
158. Degradation of CFTR by the ubiquitin-proteasome pathway
159. Biochemical characterization of alpha-ketooxadiazole inhibitors of elastases
160. Elafin: An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence
161. Antileukoprotease in human skin: An antibiotic peptide constitutively produced by keratinocytes
162. Angelman syndrome
163. Proteolytic inactivation of human alpha 1 antitrypsin by human stromelysin
164. Matrix metalloproteinase inhibitors
165. Mechanism of hypochlorite-mediated inactivation of proteinase inhibition by alpha 2-macroglobulin
166. Cathepsin B and human tumor progression